Acquires Robins' antihypertensive Tenathan (bethanidine). Approved in 1981 for the treatment of hypertension, Tenathan has never been marketed in the U.S. Medco says it "intends to test bethandidine in the prevention and treatment of ventricular fibrillation," with clinical studies beginning "in the near future." Robins retains right to manufacture and market the product under a royalty agreement.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.